- Obtain two eGFR results from your transplant follow-up labs — ideally at least 6 months apart and both from stable periods (not during rejection or infection).
- Enter the earlier eGFR value and its exact date, then the more recent eGFR value and its date.
- If you have an even newer eGFR that was not part of the paired measurement (e.g., a value from last week), enter it in the "Current eGFR" field — the calculator will use that as your starting point for projecting time to target.
- Select the target eGFR threshold you want to project toward. The 15 mL/min ESKD threshold is the most common clinical endpoint; 20 mL/min is used for re-listing planning.
- Click Calculate eGFR Trend. Review the GFR slope, projected time to target, and the "if decline slowed 30%" scenario — this scenario illustrates the potential benefit of optimizing blood pressure, immunosuppression adherence, and proteinuria control.
- Bring the printed or screenshotted result to your next transplant nephrology appointment to guide discussion.
When to Use
Use this tool during any transplant nephrology follow-up visit when you have at least two eGFR values separated by three or more months. The calculator linearizes the decline to estimate the annual GFR slope and — at the current rate — how many years remain before reaching a clinically meaningful eGFR threshold (typically 15–20 mL/min/1.73 m²). It is designed to help time two high-stakes conversations: when to return to the transplant waiting list, and when to begin constructing dialysis access.
Appropriate population
Kidney transplant recipients (living or deceased donor) with a functioning allograft and a trend of declining eGFR. Most useful when eGFR is between 20 and 40 mL/min and the trajectory over the preceding 6–24 months is downward. Also useful for identifying unexpectedly rapid decline that warrants urgent evaluation for reversible causes.
When NOT to rely on it
Do not use during an episode of acute rejection, infection, or other acute illness — the values will not reflect the true chronic trajectory. Do not apply to patients without a transplant, or to those whose eGFR is already below the target threshold. The model assumes a constant linear slope; true allograft decline is non-linear and may accelerate or plateau based on immunosuppression, comorbidities, and adherence.
Pearls & Pitfalls
The slope matters more than the absolute value
An eGFR of 30 mL/min that has been stable for 5 years carries a very different prognosis than an eGFR of 30 mL/min that was 50 one year ago. Always interpret any single eGFR value in the context of its trend. A slope more negative than −3 mL/min/yr is a red flag that requires urgent evaluation for rejection, calcineurin inhibitor toxicity, recurrent disease, or obstruction.
Re-list early — ESKD waits for no one
KDIGO and the Philippine National Kidney and Transplant Institute recommend re-listing for transplantation when allograft eGFR is projected to reach 20 mL/min within 6–12 months, or when eGFR is already below 20 mL/min and declining. Waiting until dialysis starts resets the waiting-list clock and worsens long-term outcomes. Start the living-donor evaluation conversation while the allograft is still functioning — ideally with eGFR still above 20 mL/min.
Pitfalls
(1) Do not use eGFR values drawn during acute illness, dehydration, or hospitalization — they do not represent the chronic trajectory. (2) Creatinine-based eGFR overestimates true GFR in patients with low muscle mass (common in long-term transplant recipients) — a cystatin C-based or combined creatinine–cystatin C eGFR is more accurate. (3) The two-point linear model will underestimate remaining time if the decline is actually accelerating, and overestimate it if the decline is decelerating — serial monitoring every 3 months provides more accurate slope estimation than any single two-point calculation.
Allograft eGFR Trend & Time-to-Failure Calculator
Enter two dated eGFR values to estimate your allograft's annual decline rate and how long — at the current rate — before a target eGFR threshold is reached. Use this to guide conversations with your transplant team about when to re-list and when to plan dialysis access.
⚕ Linear decline model based on two data points. Actual eGFR trajectory is non-linear and varies with treatment response, complications, and adherence. Results are educational estimates only — never stored, transmitted, or used for autonomous clinical decisions. Always review with your transplant nephrologist before any management change.
Next Steps
Use the result to support — not replace — clinical judgment.
- Interpret the value against the targets shown in the calculator and the Evidence section below, in the context of the full clinical picture.
- Trend serial measurements rather than acting on a single result; confirm abnormal or unexpected values before changing management.
- Apply the relevant KDIGO / specialty-guideline threshold and document the indication.
- Escalate or refer to nephrology when results are out of range, rapidly changing, or discordant with the clinical picture — and discuss the implications with the patient.
Evidence & References
Formula & Equations
| Quantity | Equation |
|---|---|
| GFR slope (mL/min/yr) | (eGFR₂ − eGFR₁) ÷ time interval in years |
| Time to target (yr) | (Current eGFR − target eGFR) ÷ |slope| |
| Time if decline slowed 30% (yr) | (Current eGFR − target eGFR) ÷ (|slope| × 0.70) |
| Projected target date | Today's date + (years to target × 365.25 days) |
The model assumes a constant linear rate of decline between the two observed data points and projects that rate forward. The "30% slowed" scenario is not a guaranteed clinical outcome; it illustrates that a modest reduction in decline rate — achievable with optimized renin-angiotensin system blockade, blood pressure control, or immunosuppression adjustment — can meaningfully extend the time to ESKD. This is consistent with observations from the KDIGO 2009 transplant guideline that a slope steeper than −2 mL/min/yr warrants urgent evaluation and intensification of nephroprotective therapy.
Evidence & References
The linear GFR slope model is the methodological foundation of KDIGO's 2009 Clinical Practice Guideline for the Care of Kidney Transplant Recipients, which recommends monitoring eGFR at least every three months and identifies a chronic slope steeper than −2 mL/min per year as a signal for urgent nephrology review and evaluation for reversible causes. Subsequent analyses confirm that the GFR slope is independently associated with allograft loss and patient mortality, and that pre-emptive re-listing and dialysis access planning at eGFR 15–20 mL/min improves outcomes after allograft failure.
- Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155.
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117–S314.
- Kasiske BL, Israni AK, Snyder JJ, et al. The relationship between kidney function and long-term graft survival after kidney transplant. Am J Kidney Dis. 2011;57(3):466–475.
- Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int. 2002;62(5):1875–1883.
- Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4(8):1289–1295.
